SYH2053

SYH2053 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 26, 2026: “Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial”.

Intervention

1 paper studies it2 findingsUpdated

1 new paper in 30 daysSee all 1 papers on SYH2053

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 3 trials, none about aging, 1 with no results posted.

“At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”
Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trialESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.3396

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 3 trials, none about aging, 1 with no results posted
  • 2 of 2 findings with company ties
  • 3 of 3 trials sponsored by its developers
  • Human trial1

Studies in people

1 study gave SYH2053 to people and measured what changed.

What changedDesignPeopleSource

down: Decreases LDL-C-52.94% versus placebo (95% CI -62.16 to -43.73; p < 0.0001)

down: Decreases PCSK9-91.50% versus placebo (95% CI -99.80 to -83.21; p < 0.0001)

Randomized trial180 days156 people18–75 yearsPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisonESC Congress 2026 abstract, Oct 26, 2026

What did studies of SYH2053 find?

2

Studies of SYH2053 measured 2 outcomes: PCSK9 and LDL-C.

PCSK9

downin humans1

1 study
  1. SYH2053 decreases PCSK9 in humans (Primary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison) (-91.50% versus placebo (95% CI -99.80 to -83.21; p < 0.0001)).

    “At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”

    Human trialPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisoninjection300 mg180 days

    Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

    ESC Congress 2026 abstract

More on PCSK9

LDL-C

downin humans1

1 study
  1. SYH2053 decreases LDL-C in humans (Primary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison) (-52.94% versus placebo (95% CI -62.16 to -43.73; p < 0.0001)).

    “At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”

    Human trialPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisoninjection300 mg180 days

    Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

    ESC Congress 2026 abstract

More on LDL-C

Who is developing SYH2053?

1 company: CSPC Zhongnuo Pharmaceutical (Shijiazhuang).

Companies
  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang)Phase 2hypercholesterolemia and mixed hyperlipidemia, hepatic impairment

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months